This protocol provides detailed experimental steps to establish a three-dimensional in vitro culture of bladder tumor organoids derived from carcinogen-induced murine bladder cancer. Culture methods including passaging, genetic engineering, and orthotopic transplantation of tumor organoids are described.
The development of advanced tumor models has long been encouraged because current cancer models have shown limitations such as lack of three-dimensional (3D) tumor architecture and low relevance to human cancer. Researchers have recently developed a 3D in vitro cancer model referred to as tumor organoids that can mimic the characteristics of a native tumor in a culture dish. Here, experimental procedures are described in detail for the establishment of bladder tumor organoids from a carcinogen-induced murine bladder tumor, including culture, passage, and maintenance of the resulting 3D tumor organoids in vitro. In addition, protocols to manipulate the established bladder tumor organoid lines for genetic engineering using lentivirus-mediated transduction are described, including optimized conditions for the efficient introduction of new genetic elements into tumor organoids. Finally, the procedure for orthotopic transplantation of bladder tumor organoids into the wall of the murine bladder for further analysis is laid out. The methods described in this article can facilitate the establishment of an in vitro model for bladder cancer for the development of better therapeutic options.
Bladder cancer is the most prevalent urinary tract cancer, with approximately 165,000 patients dying annually1. Among the various types of bladder cancer, muscle-invasive urothelial carcinoma exhibits an aggressive phenotype, and its 5 year survival rate is lower than 50%2. Novel therapeutic options for invasive urothelial tumors have not been expanded over the last few decades1.
Cancer cell lines have been extensively used for drug screening3. Although favorable results have been observed in numerous drug candidates in cancer cell lines, poor results are reported in clinical trials4. Following increased adaptation to in vitro two-dimensional (2D) culture environments, it has become increasingly difficult to recapitulate native tumors in cell lines. Animal cancer models or patient-derived tumor xenografts can be used to address the limitations observed in bladder cancer cell lines. However, animal cancer models are time and resource intensive. Therefore, improved disease models have been on demand for years and a novel model system, organoids, has been developed to overcome the shortcomings of existing models5.
An organoid is a multicellular 3D construct that can recapitulate in vitro the physiological characteristics of its corresponding in vivo organ. Normal and tumor organoids can be derived from either pluripotent or adult stem cells, and primary tumor cells, respectively5,6. Over the last several years, tumor organoids have been established from a large number of diverse tumor tissues7, including colon8,9, bladder10, pancreas11,12, prostate13, liver14, and breast15 tumor tissues. Such tumor organoids mimic their original tumors phenotypically and genetically. Due to their similarity to in vivo tumor tissues and their numerous practical applications, researchers have adopted them as novel disease models in the study of cancer pathogenesis.
Here, the procedures for the establishment of tumor organoids from a carcinogen-induced murine invasive urothelial tumor16 are laid out. N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) is used as a carcinogen to induce invasive urothelial carcinoma in mice17 and the tumor organoids, which exhibit the pathological characteristics of mouse muscle-invasive bladder tumors, are established from the BBN-induced murine bladder cancer16. The method to genetically manipulate the tumor organoids is illustrated using lentivirus-mediated transduction to develop a model system for studying the molecular basis of the development of bladder cancer. In addition, a method for transplanting organoids orthotopically into a bladder to investigate the role of the native bladder environment in bladder cancer is described.
All procedures were approved and conducted under the guidelines of the Institutional Animal Care and Use Committee at POSTECH (IACUC number: POSTECH-2019-0055).
1. In Vitro Culture of Bladder Tumor Organoids
2. Genetic Manipulation of Bladder Tumor Organoids Using Lentivirus-mediated Transduction (Figure 2A)
3. Orthotopic Transplantation of Bladder Organoid (Figure 3A)
In vitro culture of mouse bladder tumor organoids
The number of tumor cells dissociated from an ~1 cm3 BBN-induced tumor is at least 4 x 105 cells. When the cells are initially seeded in the basement membrane matrix, non-cancerous cells and debris may be observed. Debris was gradually diluted out by continuing the subculture. Figure 1B shows images of the cultured organoids at different time points. If the tumor cells do not form tumor organoids, the cells are potentially dead during the dissociation step. In such a case, dissociation procedures including incubation time with the enzyme need to be adjusted to increase cell viability.
Expression of GFP in bladder tumor organoids using lentivirus-mediated genetic manipulation
Bladder tumor organoids exhibited strong GFP signals with successful lentiviral infection (Figure 2B). After concentration, a total of 250 µL of virus-containing media was enough to infect 3 x 104 single tumor cells on the basement membrane matrix, maintaining 90%–100% infection efficiency. GFP signals could be detected from the bladder tumor organoids 3 days after lentiviral transduction. If the fluorescence signals are low, the efficiency of viral infection is potentially low. This can be due to numerous factors, such as low viral titer, and the procedures need to be adjusted accordingly.
Orthotopic transplantation of bladder tumor organoids
A bladder tumor allograft obtained from BBN-induced bladder tumor organoids is presented in Figure 3B16. Bladder tumor allografts were harvested 3 weeks after orthotopic transplantation. The histology of the transplanted bladder tumor was analyzed using H and E staining. Orthotopic transplants of tumor organoids can grow as bladder tumors for 2–3 weeks.
Figure 1: In vitro culture of mouse bladder tumor organoids. (A) Schematic diagram for the establishment of mouse bladder tumor organoids. (B) Representative images for the culture of bladder tumor organoids at different time points. Mouse bladder tumor organoids were established and cultured over 9 days. Scale bar = 100 µm. Please click here to view a larger version of this figure.
Figure 2: Expression of GFP in bladder tumor organoids using lentivirus-mediated genetic manipulation. (A) Schematic diagram of lentiviral transfection and transduction of bladder tumor organoids. (B) Representative images of bladder tumor organoids expressing GFP. Scale bars = 100 µm. Please click here to view a larger version of this figure.
Figure 3: Orthotopic transplantation of bladder tumor organoids. (A) Schematic diagram of orthotopic transplantation of bladder tumor organoids to a nude mouse. (B) Representative images of bladders and H and E stained sections from mice orthotopically transplanted with bladder tumor organoids. Magnified views of the boxed regions in the middle panels are shown in the left panels. Scale bar = 500 µm. This figure was reproduced from Figure 1–Figure Supplement 1, Kim et al.16, published under the Creative Commons Attribution 4.0 International Public License (CC BY 4.0; https://creativecommons.org/licenses/by/4.0/). Please click here to view a larger version of this figure.
Mouse bladder tumor organoids medium | |
Advanced DMEM/F-12 (Basic medium) | 10 mM HEPES(pH 7.4) |
10 mM Nicotinamide | 0.5x Serum-free supplement |
2 mM L-alanyl-L-glutamine dipeptide | 1% Penicillin/Streptomycin |
1 mM N-acetyl-L-cysteine | 50 ng/mL Murine epidermal growth factor |
1 µM A 83-01 |
Table 1: Composition of bladder tumor organoid medium.
This protocol describes the experimental procedures to culture and maintain bladder tumor organoids derived from carcinogen-induced murine bladder tumors.
In this protocol, there are several experimental steps in which the procedures might need some troubleshooting. First, the number of tumor cells that are initially seeded is a critical factor because low numbers of tumor cells in culture (<2 x 104 cells) mostly lead to cell death due to lack of interactions among tumor cells. In contrast, beginning with too many cells (>5 x 104 cells) at seeding leads to overcrowded organoids, resulting in difficulty when handling cultures with poor growth of each organoid. It is strongly suggested that multiple plates with different numbers of cells be established at the beginning to optimize the experimental conditions. Identifying the right number of initial tumor cells is crucial to achieve the highest cell viability and to establish successful bladder tumor organoids. Also, in long-term culture of over 2 weeks without passaging, most tumor organoids stop growing, potentially due to inadequate supply of nutrients at the center of the organoids and the depletion of growth factor in the basement membrane matrix. Therefore, subculturing organoids in a timely manner is a critical step to maintain tumor organoid culture.
Second, the production of high-titer lentiviral particles is critical for the efficient genetic manipulation of tumor organoids. To troubleshoot virus titer-related issues, it is strongly suggested that the virus titers be determined before viral transduction every time because lentiviral constructs tend to produce viral particles with varying efficiency. If tumor organoids exhibit low viability following viral infection, it is likely that the viral titers are potentially too high. It is strongly suggested to use lower amount of virus in this case. Third, during orthotopic transplantation of BBN-induced bladder tumor organoids, it is critical to maintain the integrity of the bladder wall. In case that the injection reaches the lumen of the bladder by penetrating the bladder wall layer, the experiment should be terminated and discarded. If possible, the monitoring of bladder tumor growth using an ultrasound imaging system is recommended.
One limitation of the current techniques is the absence of the tumor microenvironment or stroma in these organoids. To overcome this issue, it is strongly suggested that the orthotopic transplantation of tumor organoids use an in vivo system to mimic the native tumor microenvironment. In the future, it will be necessary to develop 3D in vitro organoid systems that are composed of tumor organoids with other components of tumor stroma.
One of the major implications of our technique is that, in orthotopic transplantation of tumor organoids, only 10 bladder tumor organoids can induce tumor growth in the bladder. Compared to the conventional tumor transplantation experiments that require 5 x 105–1 x 106 single bladder tumor cells, our methods are much more efficient and robust. Another significant difference is that the organoids can be diversely manipulated using various lentiviral vectors, such as lentiviral constructs containing short-hairpin RNA, the CRISPR–Cas9 system, or genes of interest. These would be powerful tools to add to current organoid technology. Overall, the experimental approaches presented here can facilitate the establishment of in vitro tumor models that can improve our understanding of the pathogenesis of bladder cancer rather than using 2D bladder cancer cell lines.
This method was able to establish bladder tumor organoids derived from a carcinogen-induced murine bladder tumor. The article provides a description of the lentivirus-mediated experimental procedures through which the genetic modifications are introduced and stably maintained in bladder tumor organoids. In addition, a procedure for orthotopic transplantation of tumor organoids is included. In combination with current in vivo cancer models, this technique will be a useful tool to study the molecular basis of bladder tumorigenesis.
The authors have nothing to disclose.
This research was supported by grants from the National Research Foundation of Korea to K.S: NRF-2017R1A2B4006043, NRF-2017M3C7A1047875, NRF-2017R1A5A1015366, Creative Economy Leading Technology Development Programme (SF317001A), POSCO (2018Y060) and the BK21 Plus Research Fellowship.
0.45 µm syringe filter (PES membrane) | Millipore | SLHP033RS | |
10 cm culture plate | Eppendorf | 0030-702-115 | |
90 mm Petri dish | SPL | 10090 | |
100 µm cell strainer | Corning | 352360 | |
15 mL conical tube | SPL | 50015 | |
24-well plate | Corning | 3526 | |
29 G 1/2 insulin syringe | SHINA | B299473538 | |
3 mL syringe | Norm-ject | N7.A03 | |
50 mL conical tube | SPL | 50050 | |
A8301 | Tocris | 2939 | stock concentration: 25 mM |
Absolute ethanol | Daejung | 4023-2304 | |
Absorbable suture | Henry Schein | 039010 | |
Advanced DMEM/F-12 | Thermo | 12634028 | |
Ammonium-chloride-potassium (ACK) lysing buffer | Thermo | A1049201 | |
B-27 | Gibco | 17504-044 | stock concentration: 50X |
BBN(N-butyl-N-(4-hydroxybutyl) nitrosamine) | Tokyo Chemical Industry | B0938 | |
Blue nylon 5/0-13mm | AILEE | NB521 | |
C57BL Mouse | The Jackson Laboratory | 000664 | |
CAnN.Cg-Foxn1nu/Crl (nude mouse) | Charles River | 194 | |
Collagenase type I | Thermo | 17100017 | stock concentration: 20 mg/mL |
Collagenase type II | Thermo | 17100015 | stock concentration: 20 mg/mL |
Collagenase/dispase | Sigma | 10269638001 | stock concentration: 1 mg/mL |
Cyrovial | Corning | 430488 | |
DMEM(Dulbecco's modified minimum essential media) | Gibco | 11965-118 | |
DMSO(Dimethyl sulfoxide) | Sigma | D8418 | |
DPBS(Dulbecco's phosphate-buffered saline) | Welgene | LB 001-02 | |
Enrofloxacin (Baytril) | Bayer Healthcare | DIN: 02169428 | |
FBS(Fetal bovine serum) | Millipore | ES009B-KC | |
Glutamax | Gibco | 35050061 | 100X |
HEK 293T | ATCC | CRL-11268 | |
HEPES(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) | Welgene | BB001-01 | |
Isoflurane | Hana Pharm Co., Ltd. | ||
Ketoprofen (Anafen) | Merial | DIN: 02150999 | |
Matrigel growth factor reduced (GFR) Growth Factor Reduced (GFR) |
Corning | 354230 | use for organoid culture in plate |
Matrigel high concentration (HC) | Corning | 354248 | use for organoid transplantation |
1.5 mL microtube | Axygen | MCT-150-C | |
LT1 transfection reagent | Mirus Bio | MIR 2300 | |
murine EGF(epidermal growth factor) | Peprotech | 315-09 | stock concentration: 100 µg/mL |
N-acetyl-L-cysteine | Sigma | A9165 | stock concentration: 200 mM |
Nicotinamide | Sigma | N0636 | stock concentration: 1M |
Opti-MEM | Gibco | 31985070 | |
pCMV.R 8.74 | Addgene | 22036 | Packaging plasmid |
Penicillin/streptomycin | Gibco | 15140122 | 100X |
pMD2.G | Addgene | 12259 | Envelope plasmid |
Polybrene(hexadim ethrine bromide) | Sigma | H9286 | stock concentration: 2 µg/mL |
pSiCoR | Addgene | 11579 | Lentiviral plasmid |
Razor blade | |||
Saline buffer | JW Pharmaceutical | ||
SW41Ti swinging bucket rotor | Beckman Coulter | ||
Thermolysin, Bacillus thermoproteolyticus | Millipore | 58656-2500KUCN | stock concentration: 250 KU/mL |
Trypsin-EDTA (0.25%) | Gibco | 25200072 | |
Ultracentrifugation tube | Beckman Coulter | 331372 | |
Y-27632 dihydrochloride | Abmole | M1817 | stock concentration: 10 mM |